European OTC Switch Still Muted By Regulatory Resistance

25 Jun 2012

• By Faraz Kermani

OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.

Europe’s OTC sector continues to look for a more effective Rx-to-OTC switch process as the continent’s pharmaceutical industry weathers the economic storm.

At the 48th annual meeting of the Association of the European Self-Medication Industry (AESGP), June 6-8 in Nice, France, association...